Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,229Revenue $M274Net Margin (%)30.5Z-Score28.1
Enterprise Value $M2,078EPS $1.6Operating Margin %47.7F-Score7
P/E(ttm))23.7Cash Flow Per Share $0.4Pre-tax Margin (%)48.2Higher ROA y-yY
Price/Book6.710-y EBITDA Growth Rate %0Quick Ratio6.0Cash flow > EarningsN
Price/Sales6.15-y EBITDA Growth Rate %29.2Current Ratio7.1Lower Leverage y-yY
Price/Cash Flow14.2y-y EBITDA Growth Rate %966ROA % (ttm)33.3Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)2ROE % (ttm)38.4Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M35.8ROI % (ttm)8.9Gross Margin Increase y-yY

Gurus Latest Trades with LCI

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
Current Price Change from Average Comment Current Shares
LCIJoel Greenblatt 2014-12-31 Add0.25%$40.3 - $57.52
$ 62.2734%Add 238.24%1,026,029
LCIJoel Greenblatt 2014-09-30 Add0.12%$34.05 - $51.19
$ 62.2757%Add 749.49%303,345
LCIJoel Greenblatt 2014-06-30 Buy 0.02%$29.62 - $49.76
$ 62.2759%New holding, 35709 sh.35,709
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

LCI is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
LCI Joel Greenblatt 2014-12-311,026,0292.870.36+238.24%
Premium Most recent portfolio changes are included for Premium Members only!

LCI: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Drabik David ADirector 2015-02-18Sell12,500$61.552.23view
BEDROSIAN ARTHUR PCEO 2015-02-17Sell5,000$59.895.06view
Landis G. MichaelPrincipal Accounting Officer 2015-02-17Sell11,500$58.67.37view
FARBER JEFFREYDirector 2015-02-13Sell35,000$58.188.15view
SMITH KEVINVice President 2015-02-11Sell109,436$56.5111.34view
FARBER DAVID10% Owner 2015-02-09Sell2,500$5514.4view
Landis G. MichaelPrincipal Accounting Officer 2015-02-06Sell12,049$52.9318.87view
FARBER DAVID10% Owner 2015-01-26Sell7,500$5025.84view
BEDROSIAN ARTHUR PCEO 2015-01-15Sell5,000$43.544.64view
FARBER DAVID10% Owner 2015-01-15Sell5,000$43.5244.58view

Press Releases about LCI :

    Quarterly/Annual Reports about LCI:

    News about LCI:

    Articles On GuruFocus.com
    My Stocks Feb 13 2015 
    My Stocks Feb 13 2015 
    Lannett Company Looks Cheap At First Glance; But It Is Actually Much Cheaper Than It Looks Dec 29 2014 
    comment on LCI Nov 19 2012 
    comment on LCI Nov 13 2012 
    comment on LCI Jan 26 2012 
    comment on LCI Jan 26 2012 
    comment on LCI Jan 23 2012 
    comment on LCI Jan 23 2012 
    Lannett Company Inc Reports Operating Results (10-Q) Nov 12 2010 

    More From Other Websites
    Roche's Avastin Gets Positive Opinion for Cervical Cancer - Analyst Blog Mar 02 2015
    Dow Leads As Stocks Pare Gains; Disney, Visa Mark Record Highs Mar 02 2015
    3 Pharmaceutical Stocks Set for Massive Earnings Growth in 2015 - Stocks in the News Mar 02 2015
    Keryx Biopharmaceuticals' Q4 Loss Wider than Expected - Analyst Blog Mar 02 2015
    Aurinia Pharmaceuticals (AUPH) Jumps: Stock Rises 14.9% - Tale of the Tape Mar 02 2015
    Akorn, Avago Lead IBD 50 Stocks In Earnings Growth Feb 28 2015
    Stocks Slip, But Tumi Briefly Clears Buy Point Feb 27 2015
    Strength Seen in ArQule (ARQL): Stock Soars 19.4% - Tale of the Tape Feb 27 2015
    Lannett to Present at the 27th Annual ROTH Conference on March 9 Feb 27 2015
    LANNETT CO INC Files SEC form 8-K, Regulation FD Disclosure Feb 26 2015
    United Therapeutics Beats on Q4 Earnings & Revenues - Analyst Blog Feb 25 2015
    Pacira Misses Earnings Estimates in Q4, Revenues In Line - Analyst Blog Feb 25 2015
    Merck Strikes Deal with NGM to Develop Novel Biologics - Analyst Blog Feb 24 2015
    Novartis' Farydak Approved for Multiple Myeloma with Warning - Analyst Blog Feb 24 2015
    Lannett Joins Big-Game Hunt For Drugmaker Acquisitions Feb 24 2015
    Lannett to Present at the RBC Capital Markets 2015 Healthcare Conference on February 24 Feb 24 2015
    Five Top-Rated Medical Stocks To Keep Monitoring Feb 23 2015
    Novo Nordisk's Oral Semaglutide Positive in Diabetes Study - Analyst Blog Feb 23 2015
    Stocks Slip As Europe Weighs; Deere, Boise, Lannett Slide Feb 20 2015
    Nasdaq Climbs Modestly As Indexes Close Mixed Feb 19 2015
    Oncolytics Biotech Completes Enrolment for Reolysin Study - Analyst Blog Feb 19 2015
    Actavis Tops Views, Announces Name Change To Allergan Feb 18 2015
    Lannett beats 2Q profit forecasts Feb 04 2015
    Lannett beats 1Q profit forecasts Nov 03 2014
    3/27/14 Lannett to Present at the 13th Annual Needham Healthcare Conference on April 8, 2014 Mar 27 2014
    3/6/14 Lannett to Present at the 26th Annual Roth Conference on March 12 Mar 05 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial